Login to Your Account


PMV Pharmaceuticals Inc., a company developing cancer therapies to restore p53, a protein commonly mutated in tumors, has landed a $74 million series B financing.

TAIPEI, Taiwan – Calling its recent FDA orphan designation for small-molecule drug CX-4945 in cholangiocarcinoma an important milestone, 2012 startup Senhwa Biosciences Inc. enters 2017 with plans for an uplisting on the Taiwan stock exchange.

LONDON – Following a total corporate makeover and a revamp of its technology, Realm Therapeutics plc has announced its rebirth with the filing of an FDA IND for a phase II study of its lead product, PRO22.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: